Monday, December 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Pfizer Stock: Morgan Stanley Raises Target Amid Strong Earnings

Felix Baarz by Felix Baarz
August 6, 2025
in Stocks
0
Pfizer Stock
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Pfizer’s stock received a boost as Morgan Stanley raised its price target from $32 to $33, reflecting optimism after the pharmaceutical giant reported better-than-expected Q2 results. Adjusted earnings surged 20% year-over-year to $9.6 billion, while revenue grew modestly to $28.4 billion. The company outperformed analyst estimates with Q2 earnings of $0.78 per share, 37% above projections, and revenue of $14.7 billion versus $13.47 billion expected. Management also raised its full-year adjusted EPS guidance to $2.90–$3.10, citing cost-cutting measures and strong performance from drugs like Eliquis and Xeljanz.

Regulatory Risks Loom Despite Growth

While Pfizer’s fundamentals remain strong, regulatory challenges cast a shadow. Potential U.S. tariffs of up to 250% on drug imports and government-mandated price cuts threaten profitability. The company has factored these risks into its 2025 outlook, but investor sentiment remains mixed. Shares rose 5% post-announcement, trading at $24.50, significantly outpacing the S&P 500. Analysts note the stock’s recovery from pandemic lows but caution that regulatory decisions could dictate its future trajectory.

Ad

Pfizer Stock: Buy or Sell?! New Pfizer Analysis from December 22 delivers the answer:

The latest Pfizer figures speak for themselves: Urgent action needed for Pfizer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 22.

Pfizer: Buy or sell? Read more here...

Tags: Pfizer
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Uber Stock

Uber Stock: Strong Earnings Met With Market Skepticism

LifeMD Stock

LifeMD Stock: Plunge Amidst Earnings Shock and Growth Concerns

AMD Stock

AMD Stock: Mixed Results Amid China Export Woes

Recommended

Metaplanet Stock

Metaplanet’s Debt Strategy Sparks Investor Concern

4 weeks ago
Amphenol Stock

Amphenol: A Clash of Investment Titans

1 month ago
AES Stock

AES Shares Surge Amid Intensifying Acquisition Drama

2 months ago

Aptevo Therapeutics Q4 Financial Results Key Takeaways and Future Outlook

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Metaplanet’s Strategic Pivot: A Crucial Week for Japan’s Bitcoin Giant

Plug Power’s Strategic Pivot: Execution Takes Center Stage

Hims & Hers Charts North American Growth with Canadian Market Entry

ServiceNow Shares Navigate Post-Split Turbulence Amid Acquisition Talks

Pfizer Shares Face a Multifaceted Squeeze

IonQ Secures Major European Contract Extension Valued at Over $60 Million

Trending

Corteva Stock
Analysis

Corteva Faces Index Rebalancing Amid Strategic Shifts

by Andreas Sommer
December 22, 2025
0

Shares of agricultural science company Corteva are in focus today due to a significant index change and...

Abbott Laboratories Stock

Abbott Laboratories Gains Momentum with Key Regulatory Approval

December 22, 2025
Vulcan Energy Stock

Diverging Views on Vulcan Energy’s Market Trajectory

December 22, 2025
Metaplanet Stock

Metaplanet’s Strategic Pivot: A Crucial Week for Japan’s Bitcoin Giant

December 22, 2025
Plug Power Stock

Plug Power’s Strategic Pivot: Execution Takes Center Stage

December 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Corteva Faces Index Rebalancing Amid Strategic Shifts
  • Abbott Laboratories Gains Momentum with Key Regulatory Approval
  • Diverging Views on Vulcan Energy’s Market Trajectory

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com